Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Squamous Cell Carcinoma of Head and Neck 12Oropharyngeal Neoplasms 12Prostatic Neoplasms 11Head and Neck Neoplasms 7Nasopharyngeal Carcinoma 6Carcinoma, Squamous Cell 6Esophageal Neoplasms 5Rectal Neoplasms 4Mouth Neoplasms 4Laryngeal Neoplasms 4Glioma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Papillomavirus Infections 2Oligodendroglioma 2Myelodysplastic Syndromes 2Lymphatic Metastasis 2Leukemia, Myeloid, Acute 2Hypopharyngeal Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma 2Astrocytoma 2Anus Neoplasms 2Virus Diseases 1Vaginal Neoplasms 1

Interventions

trametinib 3pembrolizumab 2lenvatinib 2dabrafenib 2Paclitaxel 2Nivolumab 2selpercatinib 1fludarabine 1cobimetinib 1atezolizumab 1aldesleukin 1Vemurafenib 1Taxes 1Radiotherapy, Intensity-Modulated 1Ipilimumab 1Immunoglobulin G 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Carcinoma, Anaplastic × Radiotherapy, Intensity-Modulated × Clear all
NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡